Eli Lilly and Company (NYSE:LLY) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Eli Lilly and Company (NYSE:LLY) have earned a consensus rating of “Moderate Buy” from the thirty analysts that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, twenty-three have assigned a buy rating and two have given a strong buy rating to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $1,222.2222.

Several equities research analysts recently weighed in on the stock. Rothschild & Co Redburn increased their target price on shares of Eli Lilly and Company from $775.00 to $830.00 and gave the company a “neutral” rating in a research note on Monday, January 26th. Royal Bank Of Canada assumed coverage on Eli Lilly and Company in a research note on Tuesday, February 24th. They set an “outperform” rating and a $1,250.00 price target on the stock. Bank of America raised their price objective on Eli Lilly and Company from $1,293.00 to $1,294.00 and gave the stock a “buy” rating in a research report on Thursday. Weiss Ratings reissued a “buy (b)” rating on shares of Eli Lilly and Company in a report on Friday, March 27th. Finally, Guggenheim lowered their price objective on Eli Lilly and Company from $1,168.00 to $1,163.00 and set a “buy” rating on the stock in a research report on Monday.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: FDA approval and commercial launch for Foundayo expands Lilly’s obesity franchise, with company pricing/distribution plans that could drive multi‑billion dollar sales and broaden patient access. Lilly’s weight-loss pill wins US approval
• Positive Sentiment: Bank of America reiterates a Buy stance and calls Foundayo the preferred oral GLP‑1, supporting upside to revenue/consensus and providing analyst backing for the stock. Bank of America sees Eli Lilly’s Foundayo as preferred oral GLP-1
• Positive Sentiment: Strategic diversification via the Centessa acquisition (≈$7.8B) broadens Lilly’s pipeline into neuroscience and non‑metabolic areas, reducing single‑market concentration risk over time. LLY to Buy Neuroscience Biotech Centessa Pharmaceuticals in $7.8B Deal
• Neutral Sentiment: Options and retail activity: unusually high call volume and large options trades indicate speculative positioning and hedging that can amplify intraday moves. Eli Lilly and Company Target of Unusually High Options Trading
• Neutral Sentiment: Street revenue estimates and models see Foundayo delivering up to billions in debut-year sales, but models vary widely and will hinge on formulary access and real‑world efficacy. Wall Street sees multi-billion dollar debut for Lilly’s obesity pill despite Novo lead
• Negative Sentiment: Novo Nordisk published cross‑trial comparisons claiming its oral Wegovy pill delivers greater weight loss and fewer adverse events versus Foundayo — a headline that can pressure Lilly shares by suggesting competitive efficacy/positioning risks. Novo Nordisk Wegovy Data Challenges Foundayo And Resets Valuation Debate
• Negative Sentiment: Macro and policy risks (geopolitical tensions and reports of potential tariffs on branded drugs) are weighing on healthcare stocks broadly and could compress multiples or dent international pricing/ margins. Trump Administration Unveils Up to 100% Tariff on Branded Drugs

Eli Lilly and Company Trading Up 0.0%

Shares of LLY stock opened at $935.85 on Friday. The firm has a market capitalization of $884.21 billion, a P/E ratio of 40.78, a price-to-earnings-growth ratio of 1.11 and a beta of 0.51. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,133.95. The firm’s fifty day simple moving average is $996.24 and its 200 day simple moving average is $966.65. The company has a current ratio of 1.58, a quick ratio of 1.19 and a debt-to-equity ratio of 1.54.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, beating analysts’ consensus estimates of $7.48 by $0.06. The firm had revenue of $19.29 billion during the quarter, compared to the consensus estimate of $17.85 billion. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The business’s revenue was up 42.6% on a year-over-year basis. During the same period in the prior year, the firm earned $5.32 EPS. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, sell-side analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Institutional Investors Weigh In On Eli Lilly and Company

Several institutional investors and hedge funds have recently bought and sold shares of LLY. 10Elms LLP raised its position in Eli Lilly and Company by 33.3% in the third quarter. 10Elms LLP now owns 40 shares of the company’s stock worth $31,000 after purchasing an additional 10 shares in the last quarter. M.E. Allison & CO. Inc. boosted its holdings in Eli Lilly and Company by 0.7% during the fourth quarter. M.E. Allison & CO. Inc. now owns 1,477 shares of the company’s stock valued at $1,587,000 after purchasing an additional 10 shares in the last quarter. Tanager Wealth Management LLP boosted its holdings in Eli Lilly and Company by 2.6% during the fourth quarter. Tanager Wealth Management LLP now owns 395 shares of the company’s stock valued at $424,000 after purchasing an additional 10 shares in the last quarter. Morey & Quinn Wealth Partners LLC grew its stake in shares of Eli Lilly and Company by 1.5% in the 4th quarter. Morey & Quinn Wealth Partners LLC now owns 661 shares of the company’s stock valued at $710,000 after purchasing an additional 10 shares during the period. Finally, Wealthspan Partners LLC grew its stake in shares of Eli Lilly and Company by 0.5% in the 4th quarter. Wealthspan Partners LLC now owns 2,110 shares of the company’s stock valued at $2,268,000 after purchasing an additional 10 shares during the period. Institutional investors own 82.53% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.